Mechanism of CYP2C9 Inhibition by Flavones and Flavonols
- 12 December 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 37 (3), 629-634
- https://doi.org/10.1124/dmd.108.023416
Abstract
This article describes an in vitro investigation of the inhibition of cytochrome P450 (P450) 2C9 by a series of flavonoids made up of flavones (flavone, 6-hydroxyflavone, 7-hydroxyflavone, chrysin, baicalein, apigenin, luteolin, scutellarein, and wogonin) and flavonols (galangin, fisetin, kaempferol, morin, and quercetin). With the exception of flavone, all flavonoids were shown to inhibit CYP2C9-mediated diclofenac 4′-hydroxylation in the CYP2C9 RECO system, with Ki value ≤2.2 μM. In terms of the mechanism of inhibition, 6-hydroxyflavone was found to be a noncompetitive inhibitor of CYP2C9, whereas the other flavonoids were competitive inhibitors. Computer docking simulation and constructed mutants substituted at residue 100 of CYP2C9.1 indicate that the noncompetitive binding site of 6-hydroxyflavone lies beside Phe100, similar to the reported allosteric binding site of warfarin. The other flavonoids exert competitive inhibition through interaction with the substrate binding site of CYP2C9 accessed by flurbiprofen. These results suggest flavonoids can participate in interactions with drugs that act as substrates for CYP2C9 and provide a possible molecular basis for understanding cooperativity in human P450-mediated drug-drug interactions.Keywords
This publication has 27 references indexed in Scilit:
- Effect of dietary flavonoids on pathways involved in drug metabolismExpert Opinion on Drug Metabolism & Toxicology, 2007
- The in Vitro Drug Interaction Potential of Dietary Supplements Containing Multiple Herbal ComponentsDrug Metabolism and Disposition, 2006
- The Potential of Flavonoids to Influence Drug Metabolism and Pharmacokinetics by Local Gastrointestinal MechanismsCurrent Drug Metabolism, 2006
- Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13Xenobiotica, 2005
- ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANSPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- Clinical consequences of cytochrome P450 2C9 polymorphismsCancer Cell, 2005
- Differential activation of CYP2C9 variants by dapsoneBiochemical Pharmacology, 2004
- Effector-Mediated Alteration of Substrate Orientation in Cytochrome P450 2C9Biochemistry, 2004
- EFFECTS OF FLAVONOIDS ISOLATED FROM SCUTELLARIAE RADIX ON CYTOCHROME P-450 ACTIVITIES IN HUMAN LIVER MICROSOMESJournal of Toxicology and Environmental Health, Part A, 2002
- Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruit juicesJournal of Agricultural and Food Chemistry, 1993